Posts

Showing posts from August, 2021

Proton Pump Inhibitors (PPI), H2 Blockers and antacids: A review

Image
  Medications for acid reflux, heartburn, and GERD (gastroesophageal reflux disease) come in three types: H2 blockers, proton pump inhibitors (PPIs), and antacids. They all work differently and are geared towards either prevention or quick relief. H2 blockers and proton pump inhibitors work better than antacids, but if you need something for very quick relief, antacids are an option. Antacids don’t do anything to prevent GERD (gastroesophageal reflux disease), but they can be used on demand for symptom relief. They are cheap and available over the counter.H2 blockers (histamine blockers) block one of the first stimuli for  acid production.  PPIs block the final step in the pathway of  acid secretion  in the stomach. In other words, the acid which has been produced (which may be reduced due to an H2 blocker) is prevented from arriving in the stomach. Of the three classes, antacids are the fastest acting. They start providing relief to the patient within five minutes. The Global Market i

Solubility Enhancement Excipient

Image
  Introduction: Poorly soluble drugs are a major issue for the pharmaceutical industry. By using solubility enhancement excipients pharmaceutical formulators can increase the bioavailability of the API. Advanced solubility enhancement excipients can help companies bring products to market faster. Nowadays most of the drug substances are coming into the innovation pipeline with poor water solubility. Here, the influence of excipients will play a significant role to improve the dissolution of poorly aqueous soluble compounds. The drug substance needs to be dissolved in gastric fluids to get the better absorption and bioavailability of an orally administered drug. Dissolution is the rate-controlling stage for drugs which controls the rate and degree of absorption. Usually, poorly soluble oral administrated drugs show a slower dissolution rate, inconsistent and incomplete absorption which can lead to lower bioavailability. The low aqueous solubility of BCS class II and IV drugs is a major